Beshom Holdings (7668) Fair Value & Analysis
Healthcare · MY · Market cap 157M MYR
Fair value as of: Jul 12, 2026
From 22 valuation models · updated 28 days ago
Fair value updated Jul 12, 2026, revised from 0.6300 MYR to 0.5500 MYR (−12.7%) since Jun 24, 2026. Share price +1.9% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from 0.4100 MYR (bear) to 0.6900 MYR (bull), base 0.5500 MYR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 63/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 0.5100 MYR – 1.76 MYR · fair‑value band 0.4100 MYR – 0.6900 MYR · the 0.5350 MYR price screens below the 0.5500 MYR fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Beshom Holdings (7668) currently trades at 0.5350 MYR, while our model-based Fair Value estimate is 0.5500 MYR, implying the stock looks roughly 2.8% fairly valued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Beshom Holdings generated revenue of 145M MYR at a net margin of 5.4%. Revenue declined 20.4% year over year. It earns a return on equity of 2.3%. The stock trades on a trailing P/E of 21.2. Fundamentals as of Jul 12, 2026
Our scenario range runs from 0.4100 MYR (bear case) to 0.6900 MYR (bull case); at 0.5350 MYR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 3%, 7668 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Asset-Based (0.6800 MYR) versus Earnings-Based (0.2100 MYR). Highest evidence: Growth DCF (80).
Notify me when 7668 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beshom Holdings Berhad, an investment holding company, engages in the wholesale and retail of herbal medicines and healthcare products in Malaysia. The company provides wholesaling and trading in patented medicines, medicated tonic, cooking wine, healthcare products, wellness, herbs, and tea.
Full company description
Beshom Holdings Berhad, an investment holding company, engages in the wholesale and retail of herbal medicines and healthcare products in Malaysia. The company provides wholesaling and trading in patented medicines, medicated tonic, cooking wine, healthcare products, wellness, herbs, and tea. It also offers multi-level direct marketing of nutritional food and beverage, wellness supplements, skincare, beauty and cosmetic, personal care and household products. In addition, it provides operating traditional complementary medicines (TCM) retail chain stores and physician consultation services. Further, it engages in manufacturing of TCM supplements; credit and leasing; insurance agency; and investment holding and property holding. The company operates retail chain stores and franchises; and multi-level-marketing branches, stockists, and sales points. The company was founded in 1975 and is headquartered in Petaling Jaya, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Beshom Holdings reported revenue of 145M MYR in FY2026 versus 210M MYR in FY2022, a compound −8.8%/yr. Reported net income was 7.9M MYR in FY2026, compounding −27.4%/yr from FY2022.
Watch 7668: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Beshom Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beshom Holdings (7668) overvalued or undervalued?
What is the fair value of 7668?
What is the quality score of 7668?
What is the revenue of Beshom Holdings (7668)?
What is the net profit margin of 7668?
Does Beshom Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beshom Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.